195 related articles for article (PubMed ID: 17979907)
1. Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
Virta L; Viramo P
J Am Geriatr Soc; 2007 Nov; 55(11):1886-7. PubMed ID: 17979907
[No Abstract] [Full Text] [Related]
2. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
[No Abstract] [Full Text] [Related]
3. Nationwide use of medicines for Alzheimer's disease by community-dwelling persons in Finland.
Alander J; Lönnroos E; Hartikainen S; Klaukka T
J Am Geriatr Soc; 2006 Mar; 54(3):557-8. PubMed ID: 16551340
[No Abstract] [Full Text] [Related]
4. Drugs for Alzheimer disease.
Can Fam Physician; 2005 Nov; 51(11):1485. PubMed ID: 16353830
[No Abstract] [Full Text] [Related]
5. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Agüera-Ortiz LF;
Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
[TBL] [Abstract][Full Text] [Related]
6. New Alzheimer's drug approved.
Health News; 2003 Dec; 9(12):2. PubMed ID: 14679975
[No Abstract] [Full Text] [Related]
7. [Anti-dementia drugs for dementia syndromes--just unkept promises?].
Ihl R
MMW Fortschr Med; 2006 May; Spec no. 2():24-6. PubMed ID: 20104710
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
9. First drug for moderate-to-severe Alzheimer's.
FDA Consum; 2004; 38(1):3. PubMed ID: 15032183
[No Abstract] [Full Text] [Related]
10. Memantine for Alzheimer's disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):73-4. PubMed ID: 12968123
[No Abstract] [Full Text] [Related]
11. Use of memantine to treat Alzheimer's disease.
Gauthier S; Herrmann N; Ferreri F; Agbokou C
CMAJ; 2006 Aug; 175(5):501-2. PubMed ID: 16940271
[No Abstract] [Full Text] [Related]
12. Variability in the prescription of cholinesterase inhibitors and memantine.
Villar-Fernández I; Bjerrum L; Feja C; Rabanaque MJ
Dement Geriatr Cogn Disord; 2009; 28(4):373-9. PubMed ID: 19887800
[TBL] [Abstract][Full Text] [Related]
13. Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study.
Paskavitz JF; Gunstad JJ; Samuel JE
Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):454-9. PubMed ID: 17267379
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.
Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
Neuroepidemiology; 2008; 31(3):193-200. PubMed ID: 18815451
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
16. [Anti-dementia therapy pays at every stage of the disease. Patients with Alzheimer's disease stay all-day fit longer].
MMW Fortschr Med; 2003 May; 145 Suppl 2():113. PubMed ID: 14579507
[No Abstract] [Full Text] [Related]
17. [Final report is now available. IQWiG doubts the effectiveness of memantine].
MMW Fortschr Med; 2009 Sep; 151(39):6. PubMed ID: 19831181
[No Abstract] [Full Text] [Related]
18. Memantine (Ebixa) in clinical practice - results of an observational study.
Calabrese P; Essner U; Forstl H
Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France.
Hommet C; Novella JL; Auriacombe S; Vercelletto M; Berrut G; Belliard S; Desmidt T; Ceccaldi M
Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):274-86. PubMed ID: 27651009
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic dose-sparing effect with addition of memantine.
Sleeper RB
Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
